Arcellx is a biotechnology company that develops cell therapies for the treatment of cancer. The company's proprietary platform technology, called ARC-SparX, enables the creation of highly targeted and potent cell therapies that can be delivered directly to tumors. Arcellx's lead product candidate, ACLX-001, is a CAR-T cell therapy that targets multiple myeloma. The company is also developing cell therapies for the treatment of solid tumors and other hematologic malignancies.